IL2, interleukin 2, 3558

N. diseases: 950; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.370 Biomarker disease BEFREE There was no significant difference in the mRNA and protein levels of iNOS, VEGF, AR and IL-2, IL-8 and TNF-α between PCa and BPH+HP groups (p > .05). iNOS, VEGF, AR and IL-2, IL-8 and TNF-α are involved in the malignant transformation of prostate tissue and play an important role in the development and progression of Prostate cancer (PCa). 29441606 2018
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.370 Biomarker disease BEFREE <b>Methods:</b> The phenotype of resting, primed (co-incubation with CTV-1 cells for 17 h) and IL-2 activated (100 IU/ml IL-2 for 17 h) NK cells isolated from frozen-thawed peripheral blood mononuclear cell (PBMC) preparations from patients with benign disease (<i>n</i> = 6) and prostate cancer (<i>n</i> = 18) and their cytotoxicity against PC3 and K562 cells was determined by flow cytometry. 30761160 2018
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.370 GeneticVariation disease BEFREE We genotyped six variants previously associated with autoimmune disease (namely rs13151961, rs13119723, rs17388568, rs3136534, rs6822844 and rs6840978) and one functional IL-2 promoter variant (rs2069762) for possible association with prostate cancer risk using the Australian Risk Factors for Prostate Cancer case-control Study. 20184734 2010
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.370 GeneticVariation disease BEFREE This study suggests that the IL-2 gene may be associated with susceptibility to prostate cancer in the Taiwan population. 17115417 2006
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.370 Biomarker disease CTD_human This study suggests that the IL-2 gene may be associated with susceptibility to prostate cancer in the Taiwan population. 17115417 2006
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.370 Biomarker disease BEFREE Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. 15076142 2004
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.370 Biomarker disease BEFREE Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. 11387054 2001
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.370 AlteredExpression disease BEFREE Since IL-2 administration seems to have an anti-tumour effect, the increased expression of this interleukin in BPH and PC could be interpreted as an attempt to hinder cell proliferation which would only be efficient at high doses. 11019784 2000